Compare Heron Therapeutics Inc (HRTX) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.66 (market cap $77.37B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 845.9× Heron Therapeutics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MDLZ | |
|---|---|---|
Market Cap | $91.46M | $77.37B |
Sector | Health | Consumer Staples |
52-Week High | $1.96 | $70.75 |
52-Week Low | $0.39 | $51.51 |
Enterprise Value | $189.36M | $97.46B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Mondelez International (MDLZ) trades at $60.15, down 1.39% today, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 28.77% gross margins and has beaten earnings estimates for three consecutive quarters. Recent corporate developments include a new CFO appointment and continued dividend payments, while analyst consensus remains strongly positive with a $68 price target representing 13% upside potential.
The outlook for MDLZ appears favorable with consistent earnings beats and solid dividend yield, though investors face risks from margin compression and commodity price volatility. Wall Street's bullish stance is supported by the company's market leadership in snacks and innovation pipeline, but execution on volume growth remains critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
